Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
607.10B
Market cap607.10B
Price-Earnings ratio
29.35
Price-Earnings ratio29.35
Dividend yield
2.06%
Dividend yield2.06%
Average volume
7.27M
Average volume7.27M
High today
$256.83
High today$256.83
Low today
$246.00
Low today$246.00
Open price
$250.00
Open price$250.00
Volume
1.95M
Volume1.95M
52 Week high
$269.43
52 Week high$269.43
52 Week low
$154.80
52 Week low$154.80

Stock Snapshot

With a market cap of 607.1B, Johnson & Johnson(JNJ) trades at $252.20. The stock has a price-to-earnings ratio of 29.35 and currently yields dividends of 2.06%.

As of 2026-07-15, Johnson & Johnson(JNJ) stock has fluctuated between $246.00 and $256.83. The current price stands at $252.20, placing the stock +2.5% above today's low and -1.8% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 1.95M, compared to an average daily volume of 7.27M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $269.43 and a 52-week low of $154.80.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $269.43 and a 52-week low of $154.80.

JNJ News

24/7 Wall St. 15m
Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner

Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner By Vandita Jadeja Published Jul 15, 10:00AM EDT Quick Read Walmart's eC...

Walmart vs Johnson & Johnson: Two Defensive Plays, Diverging Strategies and One Winner
Benzinga 44m
Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook

Adjusted earnings rose 4.7% year over year to $2.90 per share, beating the analyst consensus estimate of $2.85. Sales increased 6.6% to $25.31 billion, ahead of...

Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook
TipRanks 58m
Johnson & Johnson Stock Falls despite Q2 Beat, Higher Sales Forecast for 2026

Shares in Johnson & Johnson (JNJ) dropped about 3% early Wednesday. This came even though the U.S. pharma giant surpassed Wall Street’s sales and profit estimat...

Analyst ratings

69%

of 26 ratings
Buy
69.2%
Hold
26.9%
Sell
3.8%

More JNJ News

TipRanks 1h
Morning Movers: BlackRock climbs, J&J dips following earnings

Stock futures are modestly higher, with technology shares leading premarket gains as investors shift their attention from inflation to corporate earnings. Marke...

TipRanks 1h
Johnson & Johnson says confident in long term projections of Medtech business

08:54 EDT Johnson & Johnson says confident in long term projections of Medtech business Published first on TheFly – the ultimate source for real-time, market-m...

Investor's Business Daily 1h
Healthcare Bellwether J&J Beats And Raises, But Shares Dip

Technology Healthcare Bellwether J&J Beats And Raises, But Shares Dip Licensing Johnson & Johnson (JNJ) stock slumped early Wednesday after the healthcare giant...

Healthcare Bellwether J&J Beats And Raises, But Shares Dip
Nasdaq 3h
Johnson & Johnson Q2 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings...

Johnson & Johnson Q2 Earnings and Revenues Top Estimates
Seeking Alpha 3h
J&J falls premarket despite Q2 beats, updated guidance

Johnson & Johnson (JNJ) is down ~1.8% in premarket trading Wednesday despite posting Q2 financial results that beat on both lines and revising its 2026 revenue...

J&J falls premarket despite Q2 beats, updated guidance
The Wall Street Journal 4h
Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson raised its forecast for the year after recording higher sales. Yves Herman / Reuters Johnson & Johnson JNJ -1.52 %decrease; down pointing tri...

Johnson & Johnson Bumps Up Guidance as Sales Rise
TipRanks 4h
Genmab reports Q2 net sales of Darzalex $4.207B

Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous, or SC, product, daratumumab and hyaluro...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.